Top Industry Leaders in the Mucormycosis Market
Latest Mucormycosis Companies Update
Zydus Cadila to market TLC's mucormycosis drug in India:The Ahmedabad-based pharmaceutical company has entered into an agreement with Taiwan-based TLC to market AmphoTLC, a liposomal amphotericin B injection used to treat mucormycosis. This will help address the acute shortage of the drug in India.
Cadila Healthcare gains on agreement to market black fungus drug Shares of Cadila Healthcare rose after the company announced that it has entered into an agreement with TLC to market AmphoTLC in India. The drug is expected to address the country's shortage of liposomal amphotericin B, which is used to treat mucormycosis.
Black fungus drug news:Cipla launches Isavuconazole for mucormycosis treatment a leading Indian pharmaceutical company, has launched Isavuconazole, a new drug for the treatment of mucormycosis. The drug is expected to be a valuable addition to the limited treatment options available for this fungal infection.List of Mucormycosis Key Companies in the Market
- Abbott Laboratories (U.S.)
- Biocon Limited (India)
- Cadila Pharmaceuticals Limited (India)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche (Switzerland)
- Merck Sharp and Dohme (U.S.)
- Mylan Labs (U.S.)
- Bristol Myers Squibb (U.S.)
- Bayer AG (Germany)
- Lonza Group (Switzerland)
- Sanofi (France)
- Johnson & Johnson (U.S.)
- Pfizer Inc. (U.S.)
- Gilead Sciences (U.S.)